Login to Your Account


Dual MAb therapy targets CSCs, prevents resistance

By John Fox
Staff Writer

Friday, March 10, 2017

Combining two monoclonal antibody (MAb) cancer therapies as one treatment not only shrank bulk tumors, but also targeted the cancer stem cells (CSCs) that can be responsible for disease relapse, according to a new Chinese study reported in the March 8, 2017, edition of Science Translational Medicine.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription